Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hybrid decentralized telemedicine pilot trial of alpelisib + fulvestrant in PIK3CA-mutant HR+/HER2- advanced breast cancer
2020-005882-15Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alpelisib and fulvestrant in breast cancer, sponsored by Novartis. Primary endpoint: Participant satisfaction with DCT experience. Started Mar 2021; status: terminated.
02
Drugs
alpelisibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-005882-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005882-15.